Navigation Links
Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
Date:12/7/2007

DALLAS, Dec. 7 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it has demonstrated the ability, using the company's proprietary Cobalamin(TM) technology, to significantly reduce glucose levels in an animal model of diabetes, through its oral insulin product candidate. Several formulations using Cobalamin, which is based upon the body's natural absorption of vitamin B12 in the gastrointestinal tract, were tested in an animal model of diabetes. Additional pre-clinical studies are planned.

Access has patents and formulations based on vitamin B12 attachment to polymers and nanoparticles which carry an attached or encapsulated drug. The vitamin B12 absorption mechanism transfers the macrostructure from the gut to blood, facilitating the absorption of drugs that otherwise could not be delivered orally. Access' Cobalamin(TM) technology has the potential to enable and improve oral bioavailability of active drugs which currently have to be administered by injection, including proteins, antibodies and siRNA.

"While Access already has proof-of-principle data using this technology with a variety of proteins and peptides, we are delighted to have attained preclinical study results which indicate that a meaningful pharmacological effect can be achieved," stated Dr. David P. Nowotnik, Access' Senior Vice President, Research and Development. "As a result of this very promising result, we plan to complete a short series of formulation optimization studies and then to select a clinical development candidate."

Access intends to develop the Cobalamin(TM) oral delivery technology in collaboration with other pharmaceutical and biotechnology companies. Access has in the past and continues to conduct sponsored research programs with leading pharmaceutical companies based on its Cobalamin technology. The company is also actively seeking additional partners for both its oral insulin and other potential program
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  In part four ... leverage a hospital pharmacy as a strategic asset, ... practice leader for Cardinal Health,s Innovation Delivery Solutions business, ... can benefit both hospitals and patients. "Every ... one part of their job in a value-based healthcare ...
(Date:8/29/2014)... August 29, 2014 Pixcelldata, the ... software has announced a major new deal with Dutch ... renowned pathology expert, Dr. Marius Nap . ... 26th European Congress of Pathology which is taking placing ... Arena, London where Pixcelldata will ...
(Date:8/28/2014)... Reportlinker.com announces that a new market ... North America Aesthetic Lasers and Energy Devices ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America Aesthetic Lasers ... Summary GlobalData,s new report, "North America Aesthetic ... provides key market data on the North America ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today that ... upcoming investor conferences:   Kathryn Falberg, the ... ROTH 23rd Annual OC Growth Stock Conference in Dana Point, ... Time Bruce Cozadd, the company,s chairman and chief executive ...
... DUBLIN, March 8, 2011 Warner Chilcott plc (Nasdaq: ... of 25 million of its ordinary shares by certain ... Bain Capital Partners, J.P. Morgan Partners (advised by CCMP ... of the Company,s senior management. The offering is being ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe is ... Chuang, has joined their practice. Dr. Chuang garners extensive ... specializes in minimally-invasive arthroscopic and reconstructive treatments of the ... for patients with general and sports-related orthopedic needs. ... the medical field. As an Orange County native, he ...
(Date:8/29/2014)... based on administering antidepressants for acute and chronic ... are needed to determine whether these drugs should ... basis., Dr. Ian Gilron, a professor and director ... Anesthesiology, and his team of seven researchers reviewed ... antidepressants for pain relief post-surgery would work more ...
(Date:8/29/2014)... Colo. (Sept. 2, 2014) A team of scientists ... reported the breakthrough discovery of a process to expand ... These findings could have implications that extend beyond cancer, ... autoimmune diseases., In an article published Aug. ... Charles C. Gates Center for Regenerative Medicine and Stem ...
(Date:8/29/2014)... 29, 2014, 2 PM US Eastern Time)The current ... inject antibodies, commonly produced in animals, to neutralize ... from safety to difficulties in developing, producing and ... New research led by Charles Shoemaker, Ph.D., professor ... Health at the Cummings School of Veterinary Medicine ...
(Date:8/29/2014)... research group of Dr. John Lewis at the University of ... ON) has confirmed that "invadopodia" play a key role in ... Reports , shows preventing these tentacle-like structures from forming can ... in 5 Canadians will develop cancer in their lifetime, and ... In 2014, it,s estimated that nine Canadians will die of ...
Breaking Medicine News(10 mins):Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2Health News:Antidepressants show potential for postoperative pain 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2
... in police custody is standard operating procedure for many ... idea that using a Taser could lead to a ... final results of a study conducted by emergency medicine ... Medical Center showed no lasting effects of the Taser ...
... Some ethnic minorities could be twice as likely as ... prayer to medication for treating depression , according ... Asians who took the survey were skeptical about the ... to antidepressants, according to Jane Givens, M.D., of Boston ...
... liberated woman is certainly looking for ways and means of ... available is a bit complicated . ,Offering a ... Lybrel and the Food and Drug Administration (FDA) is expected ... meant to evoke "liberty," would be the fourth new oral ...
... traditional Indigenous land owners could help improve the overall ... ,Over the past 30 years, there has ... people who regain ownership and control of their traditional ... Research Fellow at the Jumbunna Indigenous House of Learning, ...
... the risk of diabetes in the Indigenous population, say ... Robyn McDermott, Pro-vice Chancellor of the Division of Health ... while clinical care of adults with diabetes has improved, ... ,The results, published in the latest Medical Journal ...
... the myth of big hydropower projects being clean, a ... the country are accountable for at least 19 ... ,According to the study, Indian dams are larger ... large dams could be around 33.5 million tonnes (MT) ...
Cached Medicine News:Health News:Healthy Humans Not Harmed By Taser 2Health News:Minorities Prefer Counseling and Prayer to Drugs for Treating Depression 2Health News:New Pill to Suppress Menstrual Bleeding Indefinitely 2Health News:New Pill to Suppress Menstrual Bleeding Indefinitely 3Health News:Health Benefits Of Traditional Land Ownership 2
... Immunoassay Plus Control is a ... in today's busy immunoassay laboratory. ... this human serum based control ... separate control products for immunoassay ...
... The Vidiera NsD Nucleic Sample Detection ... acids, post amplification. The new platform ... by capillary electrophoresis (CE), with software features ... and flexibility. Vidiera NsD has the ...
Invacare 5 Oxygen Concentrator, 230 VAC - Intl....
... PLUS CONCENTRATOR ANALYZER Now there is one ... parameters necessary for performing concentrator checks. Introducing ... efficient and cost-effective analyzer designed with technicians ... flow rate (L-min), and patient outlet pressure ...
Medicine Products: